Susceptibility and diversity in the therapy-refractory genus scedosporium

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 10, 2014, Pages 5877-5885

  Lackner, M ^a   Hagen, F ^b   Meis, J F ^b,c   Van Den Ende, A H G Gerrits ^d   Vu, D ^d   Robert, V ^d   Fritz, J ^a   Moussa, T A A ^e,f   De Hoog, G S ^{d,f,g,h,i,j,k}  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b CANISIUS WILHELMINA HOSPITAL   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d CBS KNAW FUNGAL BIODIVERSITY CENTRE   (Netherlands)

^e CAIRO UNIVERSITY   (Egypt)

^f KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^g UNIVERSITY OF AMSTERDAM   (Netherlands)

^h PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

ⁱ SUN YAT SEN UNIVERSITY   (China)

^j SECOND MILITARY MEDICAL UNIVERSITY   (China)

^k FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; BETA TUBULIN; INTERNAL TRANSCRIBED SPACER; MICAFUNGIN; POSACONAZOLE; RIBOSOME DNA; VORICONAZOLE; ANTIFUNGAL AGENT;

AMPLIFIED FRAGMENT LENGTH POLYMORPHISM; ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; FUNGAL STRAIN; GENOTYPE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PETRIELLIDIUM BOYDII; PSEUDALLESCHERIA; PSEUDALLESCHERIA ANGUSTA; PSEUDALLESCHERIA ELLIPSOIDEA; PSEUDALLESCHERIA FUSOIDEA; SCEDOSPORIUM; SCEDOSPORIUM APIOSPERMUM; SCEDOSPORIUM AURANTIACUM; SCEDOSPORIUM BOYDII; SCEDOSPORIUM DESERTORUM; SCEDOSPORIUM MINUTISPORUM; SPECIES DIVERSITY; SYMPATRY; DRUG EFFECTS;

ANTIFUNGAL AGENTS; PSEUDALLESCHERIA; SCEDOSPORIUM; VORICONAZOLE;

EID: 84907267822     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.03211-14     Document Type: Article

References (39)

1. Husain S, Muñoz P, Forrest G, Alexander BD, Somani J, Brennan K, Wagener MM, Singh N. 2005. Infections due to Scedosporium apiospermum and Scedosporium prolificans in transplant recipients: clinical characteristics and impact of antifungal agent therapy on outcome. Clin. Infect. Dis. 40:89-99. http://dx.doi.org/10.1086/426445.
2. Rainer J, Kaltseis J, de Hoog GS, Summerbell RC. 2008. Efficacy of a selective isolation procedure for members of the Pseudallescheria boydii complex. Antonie Van Leeuwenhoek 93:315-322. http://dx.doi.org/10 .1007/s10482-007-9206-y.
3. Lu Q, Gerrits van den Ende AHG, Bakkers JMJE, Sun J, Lackner M, Najafzadeh MJ, Melchers WJG, Li R, de Hoog GS. 2011. Identification of Pseudallescheria and Scedosporium species by three molecular methods. J. Clin. Microbiol. 49:960-967. http://dx.doi.org/10.1128/JCM.01813-10.
4. Blyth CC, Middleton PG, Harun A, Sorrell TC, Meyer W, Chen SC. 2010. Clinical associations and prevalence of Scedosporium spp. in Australian cystic fibrosis patients: identification of novel risk factors? Med. Mycol. 48(Suppl 1):S37-S44. http://dx.doi.org/10.3109/13693786.2010 .500627.
5. Raj R, Frost AE. 2002. Scedosporium apiospermum fungemia in a lung transplant recipient. Chest 121:1714-1716. http://dx.doi.org/10.1378 /chest.121.5.1714.
6. Morio F, Horeau-Langlard D, Gay-Andrieu F, Talarmin JP, Haloun A, Treilhaud M, Despins P, Jossic F, Nourry L, Danner-Boucher I, Pattier S, Bouchara JP, Le Pape P, Miegeville M. 2010. Disseminated Scedosporium/ Pseudallescheria infection after double-lung transplantation in patients with cystic fibrosis. J. Clin. Microbiol. 48:1978-1982. http://dx.doi .org/10.1128/JCM.01840-09.
7. Guarro J, Kantarcioglu AS, Horré R, Rodriguez-Tudela JL, Cuenca- Estrella M, Berenguer J, de Hoog GS. 2006. Scedosporium apiospermum: changing clinical spectrum of a therapy-refractory opportunist. Med. Mycol. 44:295-327. http://dx.doi.org/10.1080/13693780600752507.
8. Buzina W, Feierl G, Haas D, Reinthaler FF, Holl A, Kleinert R, Reichenpfader B, Roll P, Marth E. 2006. Lethal brain abscess due to the fungus Scedosporium apiospermum (teleomorph Pseudallescheria boydii) after a near-drowning incident: case report and review of the literature. Med. Mycol. 44:473-477. http://dx.doi.org/10.1080/13693780600654588.
9. Heng SC, Slavin MA, Chen SC, Heath CH, Nguyen Q, Billah B, Nation RL, Kong DC. 2012. Hospital costs, length of stay and mortality attributable to invasive scedosporiosis in haematology patients. J. Antimicrob. Chemother. 67:2274-2282. http://dx.doi.org/10.1093/jac/dks210.
10. Lackner M, de Hoog GS, Verweij PE, Najafzadeh MJ, Curfs-Breuker I, Klaassen CH, Meis JF. 2012. Species-specific antifungal susceptibility patterns of Scedosporium and Pseudallescheria species. Antimicrob. Agents Chemother. 56:2635-2642. http://dx.doi.org/10.1128/AAC.05910-11.
11. Lackner M, de Hoog GS. 2011. Parascedosporium and its relatives: phylogeny and ecological trends. IMA Fungus 2:39-48. http://dx.doi.org/10 .5598/1imafungus.2011.02.01.07.
12. Gilgado F, Cano J, Gené J, Guarro J. 2005. Molecular phylogeny of the Pseudallescheria boydii species complex: proposal of two new species. J. Clin. Microbiol. 43:4930-4942. http://dx.doi.org/10.1128/JCM.43.10 .4930-4942.2005.
13. Gilgado F, Cano J, Gené J, Sutton DA, Guarro J. 2008. Molecular and phenotypic data supporting distinct species statuses for Scedosporium apiospermum and Pseudallescheria boydii and the proposed new species Scedosporium dehoogii. J. Clin. Microbiol. 46:766-771. http://dx.doi.org/10 .1128/JCM.01122-07.
14. Rainer J, Kaltseis J. 2010. Diversity in Scedosporium dehoogii (Microascaceae): S. deficiens sp. nov. Sydowia 62:137-147.
15. Tintelnot K, Just-Nübling G, Horré R, Graf B, Sobottka I, Seibold M, Haas A, Kaben U, de Hoog GS. 2009. A review of German Scedosporium prolificans cases from 1993 to 2007. Med. Mycol. 47:351-358. http://dx.doi .org/10.1080/13693780802627440.
16. von Arx JA. 1973. The genera Petriellidium and Pithoascus (Microascaceae). Persoonia 7:367-375.
17. Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi; approved standard, 2nd ed. CLSI M38-A2. Clinical and Laboratory Standards Institute, Wayne, PA.
18. Arendrup MC, Pfaller MA. 2012. Danish Fungaemia Study Group. Caspofungin Etest susceptibility testing of Candida species: risk of misclassification of susceptible isolates of C. glabrata and C. krusei when adopting the revised CLSI caspofungin breakpoints. Antimicrob. Agents Chemother. 56:3965-3968. http://dx.doi.org/10.1128/AAC.00355-12.
19. Espinel-Ingroff A, Arendrup MC, Pfaller MA, Bonfietti LX, Bustamante B, Canton E, Chryssanthou E, Cuenca-Estrella M, Dannaoui E, Fothergill A, Fuller J, Gaustad P, Gonzalez GM, Guarro J, Lass-Flörl C, Lockhart SR, Meis JF, Moore CB, Ostrosky-Zeichner L, Pelaez T, Pukinskas SR, St-Germain G, Szeszs MW, Turnidge J. 2013. Interlaboratory variability of caspofungin MICs for Candida spp. using CLSI and EUCAST methods: should the clinical laboratory be testing this agent? Antimicrob. Agents Chemother. 57:5836-5842. http://dx.doi.org/10 .1128/AAC.01519-13.
20. Glass NL, Donaldson GC. 1995. Development of primer sets designed for use with the PCR to amplify conserved genes from filamentous ascomycetes. Appl. Environ. Microbiol. 61:1323-1330.
21. White TJ, Bruns T, Lee S, Taylor J. 1990. Amplification and direct sequencing of fungal ribosomal RNA genes for phylogenetics, p 315-322. In Innis MA, Gelfand DH, Sninsky JJ, White TJ (ed), PCR protocols: a guide to methods and applications. Academic Press, Orlando, FL.
22. Lu XL, Najafzadeh MJ, Dolatabadi S, Ran YP, Gerrits van den Ende AH, Shen YN, Li CY, Xi LY, Hao F, Zhang QQ, Li RY, Hu ZM, Lu GX, Wang JJ, Drogari-Apiranthitou M, Klaassen C, Meis JF, Hagen F, Liu WD, de Hoog GS. 2013. Taxonomy and epidemiology of Mucor irregularis, agent of chronic cutaneous mucormycosis. Persoonia 30:48-56. http://dx.doi.org/10.3767/003158513X665539.
23. Robert V, Szoke S, Jabas J, Vu D, Chouchen O, Blom E, Cardinali G. 2011. BioloMICS software, biological data management, identification, classification and statistic. Open Appl. Inform. J. 5:87-98.
24. Gilgado F, Gené J, Cano J, Guarro J. 2010. Heterothallism in Scedosporium apiospermum and description of its teleomorph Pseudallescheria apiosperma sp. nov. Med. Mycol. 48:122-128. http://dx.doi.org/10.3109 /13693780902939695.
25. Grenouillet F, Botterel F, Crouzet J, Larosa F, Hicheri Y, Forel JM, Helias P, Ranque S, Delhaes L. 2009. Scedosporium prolificans: an emerging pathogen in France? Med. Mycol. 47:343-350. http://dx.doi.org/10 .1080/13693780802454761.
26. Roilides E, Simitsopoulou M, Katragkou A, Walsh TJ. 2009. Host immune response against Scedosporium species. Med. Mycol. 47:433-440. http://dx.doi.org/10.1080/13693780902738006. Lackner et al.
27. Capilla J, Mayayo E, Serena C, Pastor FJ, Guarro J. 2004. A novel murine model of cerebral scedosporiosis: lack of efficacy of amphotericin B. J. Antimicrob. Chemother. 54:1092-1095. http://dx.doi.org/10.1093 /jac/dkh468.
28. Kaltseis J, Rainer J, de Hoog GS. 2009. Ecology of Pseudallescheria and Scedosporium species in human-dominated and natural environments and their distribution in clinical samples. Med. Mycol. 47:398-405. http://dx.doi.org/10.1080/13693780802585317.
29. Lackner M, Rezusta A, Villuendas MC, Palacian MP, Meis JF, Klaassen CH. 2011. Infection and colonisation due to Scedosporium in Northern Spain. An in vitro antifungal susceptibility and molecular epidemiology study of 60 isolates. Mycoses 54(Suppl 3):12-21. http://dx.doi.org/10 .1111/j.1439-0507.2011.02110.x.
30. Bernhardt A, Sedlacek L, Wagner S, Schwarz C, Würstl B, Tintelnot K. 2013. Multilocus sequence typing of Scedosporium apiospermum and Pseudallescheria boydii isolates from cystic fibrosis patients. J. Cyst. Fibros. 12:592-598. http://dx.doi.org/10.1016/j.jcf.2013.05.007.
31. Cuenca-Estrella M, Ruiz-Dïez B, Martïnez-Suärez JV, Monzón A, Rodrïguez- Tudela JL. 1999. Comparative in-vitro activity of voriconazole (UK-109,496) and six other antifungal agents against clinical isolates of Scedosporium prolificans and Scedosporium apiospermum. J. Antimicrob. Chemother. 43:149-151. http://dx.doi.org/10.1093/jac/43.1.149.
32. Espinel-Ingroff A, Johnson E, Hockey H, Troke P. 2008. Activities of voriconazole, itraconazole and amphotericin B in vitro against 590 moulds from 323 patients in the voriconazole phase III clinical studies. J. Antimicrob. Chemother. 61:616-620. http://dx.doi.org/10.1093/jac /dkm518.
33. Guarro J. 2011. Lessons from animal studies for the treatment of invasive human infections due to uncommon fungi. J. Antimicrob. Chemother. 66:1447-1466. http://dx.doi.org/10.1093/jac/dkr143.
34. Tortorano AM, Richardson M, Roilides E, van Diepeningen A, Caira M, Munoz P, Johnson E, Meletiadis J, Pana ZD, Lackner M, Verweij P, Freiberger T, Cornely OA, Arikan-Akdagli S, Dannaoui E, Groll AH, Lagrou K, Chakrabarti A, Lanternier F, Pagano L, Skiada A, Akova M, Arendrup MC, Boekhout T, Chowdhary A, Cuenca-Estrella M, Guinea J, Guarro J, de Hoog S, Hope W, Kathuria S, Lortholary O, Meis JF, Ullmann AJ, Petrikkos G, Lass-Flörl C. 2014. ESCMID andECMMjoint guidelines on diagnosis andmanagementof hyalohyphomycosis: Fusarium spp., Scedosporium spp. and others. Clin. Microbiol. Infect. 20(Suppl 3):27-46. http://dx.doi.org/10.1111/1469-0691.12465.
35. Rodrïguez MM, Pastor FJ, Salas V, Calvo E, Mayayo E, Guarro J. 2010. Experimental murine scedosporiosis: histopathology and azole treatment. Antimicrob. Agents Chemother. 54:3980-3984. http://dx.doi.org/10 .1128/AAC.00046-10.
36. Holle J, Leichsenring M, Meissner PE. 2013. Nebulized voriconazole in infections with Scedosporium apiospermum-case report and review of the literature. J. Cyst. Fibros. 13:400-402. http://dx.doi.org/10.1016/j.jcf .2013.10.014.
37. de Mattos Oliveira F, Unis G, Hochhegger B, Severo LC. 2013. Scedosporium apiospermum eumycetoma successfully treated with oral voriconazole: report of a case and review of the Brazilian reports on scedosporiosis. Rev. Inst. Med. Trop. Sao Paulo 55:121-123. http://dx.doi.org/10.1590/S0036-46652013000200010.
38. Lackner M, et al. 25 July 2014. Proposed nomenclature for Pseudallescheria, Scedosporium and related genera. Fungal Divers. http://dx.doi.org/10.1007/s13225-014-0295-4.
39. Hudson RR, Kaplan NL. 1985. Statistical properties of the number of recombination events in the history of a sample of DNA sequences. Genetics 111:147-164.